Literature DB >> 15913747

Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.

Eunice L Kwak1, Kenneth H Moberg, Doke C R Wahrer, Jennifer E Quinn, Paula M Gilmore, Colin A Graham, Iswar K Hariharan, D Paul Harkin, Daniel A Haber, Daphne W Bell.   

Abstract

OBJECTIVE: Archipelago (AGO, also known as hCdc4, Fbw7, or Sel-10) is an F-box containing component of the SCF complex implicated in the ubiquitination and proteolysis of cyclin E and c-Myc, and found to be mutated in 16% of endometrial carcinomas. We have previously reported somatic mutations in AGO in 3/10 ovarian cancer cell lines, but the frequency of such mutations in primary ovarian cancer is unknown.
METHODS: The coding sequence of AGO was analyzed in 95 primary sporadic ovarian tumors and 16 cases of familial ovarian cancer, and correlated with levels of cyclin E and c-Myc protein expression. Constructs encoding mutations in AGO were transfected into an AGO-null cell line to directly test their ability to regulate cyclin E and c-Myc levels.
RESULTS: Mutations were present in only 2 of 95 sporadic cases: a premature stop within the WD domain (471 Ter) and a missense change near the F-box (S245T). Both primary tumor specimens containing these mutations showed high levels of cyclin E and c-Myc, but reconstitution of an AGO-null cell line with constructs encoding these mutations showed 471 Ter to be inactive in regulating endogenous cyclin E and c-Myc levels, while the S245T mutant was indistinguishable from wild-type. No germ-line mutations were found in familial cases of ovarian cancer.
CONCLUSION: Somatic AGO mutations are infrequent in primary ovarian cancers and are unlikely to contribute to familial ovarian cancer. Reconstitution experiments, rather than measuring tumor levels of cyclin E and c-Myc, provide an effective approach to determine the functional significance of AGO mutations identified in human cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913747     DOI: 10.1016/j.ygyno.2005.04.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.

Authors:  Yan Song; Xinjia Zhou; Weiliang Bai; Xiulan Ma
Journal:  Tumour Biol       Date:  2015-01-14

Review 2.  Tumor suppressor functions of FBW7 in cancer development and progression.

Authors:  Zhiwei Wang; Hiroyuki Inuzuka; Jiateng Zhong; Lixin Wan; Hidefumi Fukushima; Fazlul H Sarkar; Wenyi Wei
Journal:  FEBS Lett       Date:  2012-03-21       Impact factor: 4.124

3.  FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer.

Authors:  Elsa De La Chesnaye; Juan Pablo Méndez; Ricardo López-Romero; María De Los Angeles Romero-Tlalolini; María Dolores Vergara; Mauricio Salcedo; Sergio R Ojeda
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  Notch signaling: switching an oncogene to a tumor suppressor.

Authors:  Camille Lobry; Philmo Oh; Marc R Mansour; A Thomas Look; Iannis Aifantis
Journal:  Blood       Date:  2014-03-07       Impact factor: 22.113

5.  Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Authors:  Shahab Akhoondi; Linda Lindström; Martin Widschwendter; Martin Corcoran; Jonas Bergh; Charles Spruck; Dan Grandér; Olle Sangfelt
Journal:  Breast Cancer Res       Date:  2010-12-01       Impact factor: 6.466

6.  FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.

Authors:  Roya Babaei-Jadidi; Ningning Li; Anas Saadeddin; Bradley Spencer-Dene; Anett Jandke; Belal Muhammad; ElSayed E Ibrahim; Ranjithmenon Muraleedharan; Mohammed Abuzinadah; Hayley Davis; Annabelle Lewis; Susan Watson; Axel Behrens; Ian Tomlinson; Abdolrahman Shams Nateri
Journal:  J Exp Med       Date:  2011-01-31       Impact factor: 14.307

7.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.

Authors:  Richard S Maser; Bhudipa Choudhury; Peter J Campbell; Bin Feng; Kwok-Kin Wong; Alexei Protopopov; Jennifer O'Neil; Alejandro Gutierrez; Elena Ivanova; Ilana Perna; Eric Lin; Vidya Mani; Shan Jiang; Kate McNamara; Sara Zaghlul; Sarah Edkins; Claire Stevens; Cameron Brennan; Eric S Martin; Ruprecht Wiedemeyer; Omar Kabbarah; Cristina Nogueira; Gavin Histen; Jon Aster; Marc Mansour; Veronique Duke; Letizia Foroni; Adele K Fielding; Anthony H Goldstone; Jacob M Rowe; Yaoqi A Wang; A Thomas Look; Michael R Stratton; Lynda Chin; P Andrew Futreal; Ronald A DePinho
Journal:  Nature       Date:  2007-05-21       Impact factor: 49.962

8.  Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.

Authors:  Kangsheng Tu; Xin Zheng; Zhenyu Zhou; Chao Li; Jing Zhang; Jie Gao; Yingmin Yao; Qingguang Liu
Journal:  PLoS One       Date:  2013-07-01       Impact factor: 3.240

9.  Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis.

Authors:  Ichiro Onoyama; Ryosuke Tsunematsu; Akinobu Matsumoto; Taichi Kimura; Ignacio Moreno de Alborán; Keiko Nakayama; Keiichi I Nakayama
Journal:  J Exp Med       Date:  2007-11-12       Impact factor: 14.307

10.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.

Authors:  Jennifer O'Neil; Jonathan Grim; Peter Strack; Sudhir Rao; Deanne Tibbitts; Christopher Winter; James Hardwick; Markus Welcker; Jules P Meijerink; Rob Pieters; Giulio Draetta; Rosalie Sears; Bruce E Clurman; A Thomas Look
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.